U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505199) titled 'Safety and Efficacy of FAP iCDC in Ischemia Cardiomyopathy' on March 26.
Brief Summary: To study the safety and efficacy of fibroblast activation protein (FAP)-targeted autologus immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of ischemic cardiomyopathy, aiming to provide a novel therapeutic strategy for the disease.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Ischemic Cardiomyopathy
Cell Therapy
Intervention:
BIOLOGICAL: autologus FAP-targeted immunosuppressive CAR-DCs (iCDC)
Each subject receives FAP-targeted immunosuppressive CAR-DCs by intravenous infusion after en...